Abstract
Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have